See more : Zespól Elektrowni Patnów-Adamów-Konin S.A. (ZEP.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Biodesix, Inc. (BDSX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodesix, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- JH Educational Technology INC. (1935.HK) Income Statement Analysis – Financial Results
- Vipul Limited (VIPUL.BO) Income Statement Analysis – Financial Results
- Regional Management Corp. (RM) Income Statement Analysis – Financial Results
- Ksolves India Limited (KSOLVES.NS) Income Statement Analysis – Financial Results
- Thanachart Capital Public Company Limited (THNUY) Income Statement Analysis – Financial Results
Biodesix, Inc. (BDSX)
About Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 49.09M | 38.21M | 54.51M | 45.56M | 24.55M | 20.43M |
| Cost of Revenue | 13.01M | 14.15M | 30.52M | 22.00M | 6.07M | 4.41M |
| Gross Profit | 36.08M | 24.06M | 23.99M | 23.56M | 18.48M | 16.03M |
| Gross Profit Ratio | 73.50% | 62.96% | 44.01% | 51.71% | 75.26% | 78.44% |
| Research & Development | 9.99M | 13.10M | 12.79M | 10.82M | 10.47M | 8.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 30.64M | 25.90M |
| Selling & Marketing | 0.00 | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| SG&A | 67.39M | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| Other Expenses | 44.00K | 109.00K | -9.00K | 422.00K | -2.38M | -1.24M |
| Operating Expenses | 77.42M | 74.56M | 63.31M | 45.68M | 41.11M | 34.09M |
| Cost & Expenses | 90.43M | 88.72M | 93.82M | 67.67M | 47.18M | 38.49M |
| Interest Income | 0.00 | 8.07M | 4.51M | 18.00K | 55.00K | 24.00K |
| Interest Expense | 9.54M | 8.07M | 4.51M | 7.60M | 3.01M | 2.92M |
| Depreciation & Amortization | 5.51M | 3.60M | 3.18M | 2.90M | 2.79M | 1.74M |
| EBITDA | -37.10M | -53.78M | -35.47M | -20.84M | -24.93M | -21.51M |
| EBITDA Ratio | -75.59% | -131.89% | -72.15% | -47.58% | -90.25% | -85.81% |
| Operating Income | -41.34M | -50.51M | -39.32M | -22.12M | -22.63M | -23.46M |
| Operating Income Ratio | -84.22% | -132.17% | -72.14% | -48.55% | -92.16% | -114.82% |
| Total Other Income/Expenses | -10.80M | -14.86M | -2.22M | -8.42M | -3.99M | -2.71M |
| Income Before Tax | -52.15M | -65.45M | -43.16M | -31.35M | -30.73M | -26.17M |
| Income Before Tax Ratio | -106.23% | -171.27% | -79.18% | -68.81% | -125.15% | -128.06% |
| Income Tax Expense | 0.00 | 14.94M | 1.32M | 5.12M | 629.00K | 211.00K |
| Net Income | -52.15M | -80.39M | -44.48M | -36.47M | -31.36M | -26.17M |
| Net Income Ratio | -106.23% | -210.37% | -81.61% | -80.06% | -127.71% | -128.06% |
| EPS | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| EPS Diluted | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| Weighted Avg Shares Out | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
| Weighted Avg Shares Out (Dil) | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
Biodesix Partners with Datavant to Enhance Value of Lung Cancer Databank
BDSX Stock Price: Over 8% Increase Pre-Market Explanation
First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker
Biodesix to Present at the William Blair 41st Annual Growth Stock Conference
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2021 Results - Earnings Call Transcript
Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans
Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021
Biodesix to Report First Quarter 2021 Financial Results on May 11, 2021
Biodesix Announces Presentation on Use of Biomarker-Based Risk Assessment to Inform Lung Nodule Management
Biodesix Announces Fourth Quarter and Full Year 2020 Results
Source: https://incomestatements.info
Category: Stock Reports